Elisa Vigna

List of Publications by Citations

50 papers	4,517 citations	26 h-index	51 g-index
51 ext. papers	4,769 ext. citations	8.9 avg, IF	4.6 L-index

#	Paper	IF	Citations
50	Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. *Oncogene*, **1991**, 6, 501-4	9.2	523
49	Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.. *EMBO Journal*, **1991**, 10, 2867-2878	13	486
48	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.. *EMBO Journal*, **1992**, 11, 4825-4833	13	393
47	Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. *Journal of Gene Medicine*, **2000**, 2, 308-16	3.5	285
46	Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. *Nature Biotechnology*, **2005**, 23, 108-16	44.5	254
45	Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. *Journal of Biological Chemistry*, **1995**, 270, 603-11	5.4	201
44	A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 11574-8	11.5	201
43	The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. *Journal of Clinical Investigation*, **2009**, 119, 2366-78	15.9	200
42	Identification of myocardial and vascular precursor cells in human and mouse epicardium. *Circulation Research*, **2007**, 101, 1255-65	15.7	193
41	Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. *EMBO Journal*, **1991**, 10, 2867-78	13	193
40	The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. *Molecular and Cellular Biology*, **1991**, 11, 1793-803	4.8	179
39	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. *Clinical Cancer Research*, **2013**, 19, 2381-92	12.9	139
38	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. *EMBO Journal*, **1992**, 11, 4825-33	13	134
37	Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. *Molecular Therapy*, **2002**, 5, 252-61	11.7	132
36	MET overexpression turns human primary osteoblasts into osteosarcomas. *Cancer Research*, **2006**, 66, 4750-7	10.1	106
35	Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.. *Journal of Biological Chemistry*, **1991**, 266, 19558-19564	5.4	105
34	Hepatocyte growth factor is a regulator of monocyte-macrophage function. *Journal of Immunology*, **2001**, 166, 1241-7	5.3	102

33	Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. *Journal of Biological Chemistry*, **1991**, 266, 19558-64	5.4	88
32	Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. *Journal of Biological Chemistry*, **2010**, 285, 36149-57	5.4	67
31	The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. *Molecular and Cellular Biology*, **1991**, 11, 1793-1803	4.8	63
30	Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. *Molecular Therapy*, **2005**, 11, 763-75	11.7	56
29	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. *Oncogene*, **1999**, 18, 4275-81	9.2	52
28	Targeting the oncogenic Met receptor by antibodies and gene therapy. *Oncogene*, **2015**, 34, 1883-9	9.2	33
27	T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. *Human Gene Therapy*, **2009**, 20, 1576-88	4.8	33
26	"Active" cancer immunotherapy by anti-Met antibody gene transfer. *Cancer Research*, **2008**, 68, 9176-83	10.1	32
25	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. *Biochemical Journal*, **1998**, 336 (Pt 1), 235-9	3.8	28
24	Met inhibition revokes IFN□nduction of PD-1 ligands in MET-amplified tumours. *British Journal of Cancer*, **2019**, 120, 527-536	8.7	26
23	Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons. *Development (Cambridge)*, **2014**, 141, 4065-75	6.6	26
22	A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. *Molecular Cancer Therapeutics*, **2013**, 12, 2459-71	6.1	25
21	Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H1875-84	5.2	24
20	CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. *OncoImmunology*, **2018**, 7, e1423167	7.2	21
19	Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. *Cancer Research*, **2016**, 76, 5019-29	10.1	16
18	Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. *Molecular Oncology*, **2015**, 9, 1760-72	7.9	15
17	MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	14
16	Retroviral vectors containing Tet-controlled bidirectional transcription units for simultaneous regulation of two gene activities. *Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research*, **2006**, 2, 107-18	2.5	13

15	Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 294, H1541-9	5.2	12
14	Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. *Molecular Oncology*, **2016**, 10, 938-48	7.9	10
13	Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. *International Journal of Cancer*, **2018**, 143, 1774-1785	7.5	8
12	Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. *Journal of Molecular Medicine*, **2014**, 92, 65-76	5.5	8
11	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. *Journal of Molecular and Cellular Cardiology*, **2016**, 93, 84-97	5.8	6
10	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. *Clinical Cancer Research*, **2020**, 26, 6321-6334	12.9	5
9	HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer. *Cancers*, **2021**, 13,	6.6	4
8	Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody. *Cancers*, **2020**, 12,	6.6	2
7	A receptor-antibody hybrid hampering MET-driven metastatic spread. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 32	12.8	2
6	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. *Biomedicines*, **2015**, 3, 124-137	4.8	1
5	Structure and functions of the HGF receptor (c-Met) **1995**, 51-70		1
4	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.. *Frontiers in Immunology*, **2021**, 12, 775151	8.4	0
3	hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of SMET-addictedScancers.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 112	12.8	0
2	Lentiviral Vectors for Cancer Gene Therapy83-94		
1	The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity **1992**, 301-310		